Although only one intravenous administration has proven to be nearly cured of spinal muscular dystrophy (SMA), the administration costs about ₩2.5 billion, increasing the demand for insurance benefits for Zolgensma (Onasemnogene Abeparvovec), which is called an "extremely high-priced one-shot treatment.

Following the U.S. and Japan, the MFDS approved Zolgensma as of May 28, but patients and guardians have appealed for drug benefits to Cheongwadae's petition as the drug price has not been set. On the 5th, the mother of a 12-month-old girl suffering from SMA posted a message urging Zolgensma to apply insurance. A total of 2,975 people agreed to the petition as of 5:30 p.m. on the 6th, about a day